ClinicalTrials.gg
RecruitingNCT07504068Updated May 4, 2026

Effects of Physical Exercise and a Nutritional Supplement on Body Composition, Metabolic Function, and Overall Health in Adults With a Metabolically Challenging Profile

An interventional study of Group 1: Exercise + thermogenic supplement (EX-TS) and Group 2: Exercise + placebo supplement (EX-PL) in Aging, Adults With Overweight and Obesity and Supplementation, sponsored by University of Valencia. Recruiting at 1 site in Spain. Open to participants aged 50 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University of Valencia · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
50 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 390 studies in Obesity with a site in Spain — 95 open to participants now, 134 under way, 45 of them phase 3. Obesity · Spain.

Planned enrollment
224th of 332
70 · median 124
Started
2026
with 42 others
No phase
220 of 390
41 open now
Primary completion
2026-07
later than 40 of 133 live
Registered
357th of 390
by date

Among the 390 studies in Obesity with a site in Spain, this one is the 224th largest by planned enrollment of the 332 interventional ones that give a count, is one of 43 that started in 2026, is one of 220 with no phase, reaches primary completion later than 40 of the 133 other live ones, and was the 357th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

95 of the 390 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:

89 more — sign in →

All 95 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 50 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Obesity with a site in Spain, or all of them as a file.
02

Study summary

Early-onset metabolic disturbances (such as mild hyperglycemia, subclinical dyslipidemia, excess body fat, and reduced functional capacity) represent one of the major public health challenges among middle-aged and older adults. Although body mass index (BMI) remains the primary clinical criterion for classifying excess weight, growing evidence indicates that BMI does not adequately discriminate cardiometabolic risk, particularly in individuals classified as overweight who present elevated body fat levels (Wu et al., 2024).

Several studies have identified altered metabolic phenotypes that do not meet the criteria for obesity, including the so-called "metabolically unhealthy normal weight" (MUNW) or "metabolically unhealthy non-obese" phenotypes. These individuals are characterized by excess body fat, central adiposity, and alterations in glucose and lipid metabolism despite having a non-obese BMI (Stefan, 2020). This profile is associated with increased insulin resistance, low-grade systemic inflammation, and elevated cardiovascular risk, underscoring the need for targeted interventions in "metabolically challenged" individuals. Xiong et al. (2024) demonstrated that metabolic health status independently predicts cardiovascular risk, even when BMI is within non-obese ranges. This evidence supports the rationale of the present project: to intervene in a group of adults without clinical obesity (BMI \< 30 kg/m²) but presenting at least two indicators of mild metabolic dysfunction.

Nutritional supplements with thermogenic properties that promote fat oxidation and satiety-such as phenylcapsaicin, an analog of capsaicin designed to improve bioavailability and reduce pungency, thereby enhancing tolerability in adults-may offer a promising complementary strategy. Recent studies have shown that low doses of phenylcapsaicin were sufficient to increase fat oxidation during exercise, reduce respiratory exchange ratio, and lower maximal heart rate during submaximal testing compared with placebo (Jiménez-Martínez et al., 2023a). Furthermore, additional research reported that phenylcapsaicin improved strength performance, reduced perceived exertion, and attenuated markers of muscle damage following resistance training (Jiménez-Martínez et al., 2023b). These findings suggest that thermogenic and fat-oxidation-enhancing supplementation may act as a safe and effective metabolic modulator, particularly when combined with exercise, positioning it as an innovative strategy for adults presenting mild metabolic risk.

The present study would integrate: (1) a multicomponent functional exercise program designed to improve strength, balance, and aerobic capacity in older adults; (2) a thermogenic and fat-oxidation-enhancing nutritional supplement as a safe metabolic activation strategy; (3) a standardized dietary control protocol to isolate the specific effects of the supplementation; (4) dual-energy X-ray absorptiometry (DXA) for precise body composition assessment; (5) hormonal and lipid biomarkers to evaluate underlying physiological mechanisms; and (6) validated questionnaires addressing quality of life, sleep, and appetite to capture the holistic dimension of this stage of adulthood.

This multidimensional approach would provide an innovative intervention for a growing yet underexplored population: non-obese but metabolically challenged adults at increasing cardiometabolic risk.

References:

  • Jiménez-Martínez P, Sánchez-Valdepeñas J, Cornejo-Daza PJ, Cano-Castillo C, Asín-Izquierdo I, Alix-Fages C, Pareja-Blanco F, Colado JC. Effects of different phenylcapsaicin doses on neuromuscular activity and mechanical performance in trained male subjects: a randomized, triple-blinded, crossover, placebo-controlled trial. Front Physiol. 2023a Aug 2; 14: 1215644.
  • Jiménez-Martínez P, Cornejo-Daza PJ, Sánchez-Valdepeñas J, Asín-Izquierdo I, Cano-Castillo C, Alix-Fages C, Pareja-Blanco F, Colado JC. Effects of different phenylcapsaicin doses on resistance training performance, muscle damage, protein breakdown, metabolic response, ratings of perceived exertion, and recovery: a randomized, triple-blinded, placebo-controlled, crossover trial. J Int Soc Sports Nutr. 2023b Dec; 20 (1): 2204083.
  • Stefan N. Metabolically healthy and unhealthy normal weight and obesity. Endocrinol Metab (Seoul). 2020 Sep;35(3):487-493.
  • Xiong Q, Zang Y, Li J, An Y, and Yu S. Comparison of cardiovascular disease risk association with metabolic unhealthy obesity identified by body fat percentage and body mass index: Results from the 1999-2020 National Health and Nutrition Examination Survey. PLoS One. 2024 Aug 14; 19 (8): e0305592.
  • Wu Y, Li D, and Vermund SH. Advantages and limitations of the body mass index (BMI) to assess adult obesity. Int J Environ Res Public Health. 2024 Jun 10; 21 (6): 757.
Read the detailed description

The present project is designed as a longitudinal, randomized, controlled, parallel-group, triple-blind clinical trial, with a 12-week active intervention and pre- and post-intervention assessments.

The study will be conducted at a single center (single-center trial) and will include two parallel groups:

  • Experimental group: multicomponent functional exercise + thermogenic and appetite-modulating nutritional supplement.
  • Control group: multicomponent functional exercise + placebo supplement (identical in appearance, without active ingredient).

Randomization will be performed using balanced block allocation, stratified by sex and baseline body fat percentage, with a 1:1 allocation ratio.

The study will be triple-blind:

  • Participants,
  • The intervention and assessment team,
  • And the statistician responsible for data analysis will remain unaware of group allocation (experimental or control).

The design corresponds to a comparative efficacy trial aimed at evaluating the additional effect of the nutritional supplement compared to placebo, while maintaining identical exercise programming and dietary control in both groups. This approach allows isolation of the specific impact of the supplement on body composition, metabolic function, functional capacity, and perceived health in adults with a metabolically challenged profile but without clinical obesity.

As is standard practice, participants will be informed that their allocation may correspond to either the placebo or experimental group, without disclosure of their actual assignment.

As appropriate in experimental studies, standardized collection of biological samples and psychometric and perceived health data will be conducted at pre- and post-intervention time points to quantify changes in these metrics and analyze them as dependent variables of the applied protocol.

03

Conditions studied

  • Aging
  • Adults With Overweight and Obesity
  • Supplementation
  • Exercise

Keywords

  • Older adults
  • Adults with metabolic disorders
  • Nutritional supplement
  • Multicomponent exercise
  • Healthy aging
  • Quality of life
  • Non-pharmacological intervention
  • Randomized controlled trial
04

Who can participate

Ages eligible
50 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Individuals will be eligible to participate in the study if they meet all of the following criteria:

  1. Age: Between 50 and 65 years at the time of screening.
  2. Weight status (non-obese): (BMI) between 25.0 and 29.9 kg/m² (overweight range, without clinical obesity).
  3. Metabolically challenged profile (non-obese): Presence of at least two of the following criteria, in addition to the specified BMI range:

    A) Altered body composition (primary criterion): Body fat percentage ≥ 30% in women or ≥ 25% in men, assessed by DXA.

    B) Borderline metabolic markers (one or more):

    • Fasting glucose: 100-125 mg/dL
    • Triglycerides: ≥ 150 mg/dL
    • HDL cholesterol: \< 50 mg/dL in women or \< 40 mg/dL in men
    • LDL cholesterol: ≥ 130 mg/dL

    C) Sedentary lifestyle:

    Low or very low physical activity level, defined as ≤ 600 MET·min/week according to the IPAQ questionnaire.

  4. Clinical and functional status:

    • Clinically stable condition, without acute disease or recent decompensation.
    • Ability to perform moderate-intensity exercise three times per week, according to medical assessment.
  5. Previous treatment and lifestyle:

    • No participation in structured exercise programs (≥ 2 days/week) during the previous 6 months.
    • No intensive hypocaloric diets or medical weight-loss treatments during the previous 3 months.
  6. Administrative and ethical aspects:

    • Ability to understand study explanations and follow instructions.
    • Signed prior to initiation of any study procedures.

Exclusion Criteria: Individuals presenting any of the following conditions will be excluded from the study:

  1. Clinical obesity or anthropometric extremes:

    • BMI ≥ 30.0 kg/m² (obesity).
    • Any weight-related or clinical condition that, in the judgment of the principal investigator, contraindicates participation.
  2. Relevant or uncontrolled chronic diseases:

    • Previous diagnosis of type 1 or type 2 diabetes mellitus.
    • Moderate or severe cardiovascular disease (e.g., ischemic heart disease, heart failure, uncontrolled arrhythmias).
    • Moderate or severe renal, hepatic, or respiratory disease.
    • Neurological or musculoskeletal disorders limiting or contraindicating the prescribed exercise program.
  3. Pharmacological treatments interfering with energy metabolism or body weight:

    Current use (or use within the previous 3 months) of:

    • Weight-loss medications or GLP-1 receptor agonists
    • Systemic at moderate or high doses
    • Thyroid hormones at non-replacement doses
    • Anabolic agents or other drugs significantly affecting body composition
  4. Specific prior supplementation: Use of capsaicin, phenylcapsaicin, or other thermogenic or appetite-modulating supplements within the previous 3 months.
  5. Functional or cognitive limitations:

    • Cognitive, psychiatric, or mental health disorders that may impair study comprehension or protocol adherence.
    • Physical limitations preventing safe participation in exercise.
  6. Substance use:

    • Alcohol consumption at levels considered high risk (> 20 g/day).
    • Heavy smoking (> 10 cigarettes/day), unless deemed clinically stable by the investigator.
  7. Other exclusion criteria:

    • Concurrent participation in another clinical trial or interventional study.
    • Any other condition that, in the judgment of the principal investigator, may pose additional risk to the participant or significantly interfere with study outcomes.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Group 1: Exercise + thermogenic supplement (EX-TS)

    Participants in this group will receive an oral daily dose of the nutritional supplement with thermogenic and appetite-modulating effects in combination with a supervised multicomponent functional exercise program (3 sessions per week, 60 minutes each) for 12 weeks

    Dietary Supplement: Group 1: Exercise + thermogenic supplement (EX-TS)

  • Placebo comparator
    Group 2: Exercise + placebo supplement (EX-PL)

    Participants in this group will receive a placebo supplement identical in appearance, color and taste to the active supplement, together with the same multicomponent functional exercise program for 12 weeks

    Dietary Supplement: Group 2: Exercise + placebo supplement (EX-PL)

Interventions

  • Dietary supplementGroup 1: Exercise + thermogenic supplement (EX-TS)

    Participants in this group will receive an oral daily dose of the nutritional supplement with thermogenic and appetite-modulating effects in combination with a supervised multicomponent functional program (3 sessions per week, 60 minutes each) for 12 weeks, composed by three exercise blocks: 1) joint mobility and postural control exercises block, 2) functional strength block with three sets of two strength exercises using elastic bands at 70%-85 of 1RM (RPE 6-7 at the beginning and 9 at the end of the set) and, 3) coordination and agility exercises block. Participants will undergo a standardized dietary control plan based on Individualized energy deficit equivalent to 0.7% of body weight per week, adjusted using the Harris-Benedict equation, and macronutrient distribution: protein: 2 g/kg; fat: 0.8 g/kg; remaining energy intake allocated to carbohydrates.

  • Dietary supplementGroup 2: Exercise + placebo supplement (EX-PL)

    Participants in this group will receive a placebo supplement identical in appearance, color and taste to the active supplement, together with the same multicomponent functional exercise program and dietary control for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in body composition via Dual-Energy X-ray Absorptiometry (DXA)

    Whole body and segmental composition will be assessed through Dual-Energy X-ray Absorptiometry (DXA). Parameters analyzed will be: total and regional fat mass and lean mass

    Time frame: Pre and post-intervention of 12 weeks

  2. Change in fat distribution via Dual-Energy X-ray Absorptiometry (DXA)

    Android/gynoid fat distribution will be analyzed through Dual-Energy X-ray Absorptiometry (DXA).

    Time frame: Pre and post-intervention of 12 weeks

  3. Change in hormonal biomarkers (glucagon-like peptide-1;GLP-1)

    glucagon-like peptide-1 (GLP-1) will be collected through a blood sample in the morning in a fasted state to assess hormonal state

    Time frame: Pre and post-intervention of 12 weeks

  4. Change in hormonal biomarkers (acylated ghrelin)

    Acylated ghrelin levels will be collected through a blood sample in the morning in a fasted state to assess hormonal state

    Time frame: Pre and post-intervention of 12 weeks

  5. Change in hormonal biomarkers (leptin)

    Leptin levels will be collected through a blood sample in the morning in a fasted state to assess hormonal state

    Time frame: Pre and post-intervention of 12 weeks

  6. Change in metabolic biomarkers (glucose)

    Glucose levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 12 weeks

  7. Change in metabolic biomarkers (total cholesterol)

    Total cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 12 weeks

  8. Change in metabolic biomarkers (HDL cholesterol)

    HDL cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 12 weeks

  9. Change in metabolic biomarkers (LDL cholesterol)

    LDL cholesterol levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 12 weeks

  10. Change in metabolic biomarkers (triglycerides)

    Triglycerides levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 12 weeks

  11. Change in metabolic biomarkers (creatine)

    Creatinine levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 12 weeks

  12. Change in metabolic biomarkers (aspartate aminotransferase; ATS)

    AST (Aspartate aminotransferase) levels will be collected through a blood sample in the morning in a fasted state to assess metabolic state.

    Time frame: Pre and post-intervention of 12 weeks

Secondary outcomes

  1. Change in body composition via bioelectrical impedance analysis (BIA)

    Whole body fat-free mass will be assessed through bioelectrical impedance analysis (BIA)

    Time frame: Pre and post-intervention of 12 weeks

  2. Changes in distance covered/aerobic capacity

    Distance covered/aerobic capacity will be assessed through the 6- Minute walking test

    Time frame: Pre and post-intervention of 12 weeks

  3. Changes in lower limb strength

    Lower limb strength will be assessed through the 30-second Chair Stand Test

    Time frame: Pre and post-intervention of 12 weeks

  4. Changes in agility and dynamic balance

    Agility and dynamic balance will be assessed through the Timed Up and Go Test

    Time frame: Pre and post-intervention of 12 weeks

  5. Changes in handgrip strength

    Handgrip strength will be assessed through the Handgrip dynamometry (Jamar Hand Dynamometer).

    Time frame: Pre and post-intervention of 12 weeks

  6. Changes in quality of life specific for older adults

    Quality of life will be assessed through the World Health Organization Quality of Life-OLD (WHOQOL-OLD) questionnaire

    Time frame: Pre and post-intervention of 12 weeks

  7. Changes in general quality of life

    Quality of life will be assessed through the Short Form-36 Health Survey (SF-36) questionnaire

    Time frame: Pre and post-intervention of 12 weeks

  8. Changes in general health perception

    General health perception will be assessed through the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) questionnaire

    Time frame: Pre and post-intervention of 12 weeks

  9. Change in sleep quality

    Sleep quality will be assessed through Pittsburgh Sleep Quality Index

    Time frame: Pre and post-intervention of 12 weeks

  10. Change in perceived insomnia

    Perceived insomnia will be assessed through the Insomnia Severity Index

    Time frame: Pre and post-intervention of 12 weeks

  11. Change in eating behavior

    Eating behavior will be assessed through the Emotional Eater Questionnaire

    Time frame: Pre and post-intervention of 12 weeks

  12. Change in appetite behavior

    Appetite behavior will be assessed through the Simplified Nutritional Appetite Questionnaire

    Time frame: Pre and post-intervention of 12 weeks

  13. Anthropometric changes (waist and hip circumferences)

    Waist circumference and hip circumference will be measured

    Time frame: Pre and post-intervention of 12 weeks

  14. Anthropometric changes (waist -hip index)

    waist -hip index will be measured

    Time frame: Pre and post-intervention of 12 weeks

  15. Anthropometric changes (waist to height index)

    waist to height index will be measured

    Time frame: Pre and post-intervention of 12 weeks

Other outcomes

  1. Adherence to supplement and exercise

    Adherence to supplement and exercise will be assessed through ad hoc questionnaire

    Time frame: Every day for nutritional supplement and each exercise session during the 12 weeks of intervention.

  2. Demographic characteristics (age)

    Age will be assessed.

    Time frame: Pre and post-intervention of 12 weeks

  3. Demographic characteristics (sex)

    Sex will be assessed.

    Time frame: Pre and post-intervention of 12 weeks

  4. Demographic characteristics (Body mass index, BMI)

    Body mass index (BMI; weight/height2) will be assessed.

    Time frame: Pre and post-intervention of 12 weeks

  5. Demographic characteristics (regular medication)

    Regular medication will be assessed.

    Time frame: Pre and post-intervention of 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Physical activity and Sport Science Faculty
    Valencia, Valencia 46010, Spain
    Recruiting
    • Juan Carlos Colado Sánchez, Chair full professor · Contactjuan.colado@uv.es
    • Juan Carlos Colado Sánchez, Chair full professor · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jul 2026, 4 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 4 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 31, 2026
StartActual
Mar 25, 2026
Primary completionEst.
Jul 30, 2026
CompletionEst.
Jul 30, 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07504068
Responsible party
Juan C. Colado (Chaired Full Professor of Physical Education, University of Valencia) — Principal investigator
First posted
Mar 31, 2026
Start date
Mar 25, 2026
Primary completion
Jul 30, 2026 (estimated)
Completion
Jul 30, 2026 (estimated)
Last update
May 4, 2026

Study contacts

Juan Carlos Colado Sánchez, Chair full professor
Contact
juan.colado@uv.es
(9639) 83470

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion